Identification of solubility-limited absorption of oral anticancer drugs using PBPK modeling based on rat PK and its relevance to human.

Fink, Christina; Lecomte, Marc; Badolo, Lassina; Wagner, Knut; Mäder, Karsten; Peters, Sheila-Annie

Fink, Christina; Lecomte, Marc; Badolo, Lassina; Wagner, Knut; Mäder, Karsten; Peters, Sheila-Annie.

Afiliação

Fink C; Chemical Pharmaceutical Development, Merck KGaA, Darmstadt, Germany; Institute of Pharmacy, Faculty of Biosciences, Martin-Luther University Halle-Wittenberg, Germany.
Lecomte M; NCE DMPK, Discovery Technology, Merck KGaA, Darmstadt, Germany.
Badolo L; NCE DMPK, Discovery Technology, Merck KGaA, Darmstadt, Germany.
Wagner K; Chemical Pharmaceutical Development, Merck KGaA, Darmstadt, Germany.
Mäder K; Institute of Pharmacy, Faculty of Biosciences, Martin-Luther University Halle-Wittenberg, Germany.
Peters SA; Quantitative Pharmacology, Merck KGaA, Darmstadt, Germany. Electronic address: sheila-annie.peters@merckgroup.com.

Eur J Pharm Sci ; 152: 105431, 2020 Sep 01.

Article em En | MEDLINE | ID: mdl-32562690

Assuntos

Desenvolvimento de Medicamentos; Modelos Biológicos; Administração Oral; Animais; Humanos; Ratos; Solubilidade

Palavras-chave

Human PK prediction; PBPK; Poorly water-soluble drugs; Rat pharmacokinetics; Solubility; Tyrosine kinase inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Desenvolvimento de Medicamentos / Modelos Biológicos Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google